VIVOZON PHARMACEUTICAL CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name VIVOZON PHARMACEUTICAL CO., LTD.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 127.7%
- Equity ratio
- 43.9%
- ROE
- -44.6%
- Op. margin
- -32.3%
- Rev. growth
- -32.3%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 1 straight year.
- Total equity is below paid-in capital: partial impairment (자본잠식), rate 42.0%.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 124.7% | 44.5% | -82.1% | -31.1% | n/a |
| FY2022 consolidated | 76.8% | 56.6% | -37.1% | -31.4% | 2.3% |
| FY2023 consolidated | 66.9% | 59.9% | -3.2% | 3.6% | 20.7% |
| FY2024 consolidated | 73.3% | 57.7% | -9.4% | 3.3% | 22.8% |
| FY2025 consolidated | 127.7% | 43.9% | -44.6% | -32.3% | -32.3% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩57.7B | ₩59.1B | ₩71.3B | ₩87.6B | ₩59.3B |
| Operating profit | -₩17.9B | -₩18.5B | ₩2.6B | ₩2.9B | -₩19.2B |
| Pre-tax income | -₩75.8B | -₩37.7B | -₩2.2B | -₩10.5B | -₩32.3B |
| Net income | -₩71.0B | -₩39.2B | -₩3.4B | -₩10.0B | -₩32.4B |
| Total assets | ₩194.5B | ₩187.1B | ₩173.6B | ₩184.4B | ₩165.5B |
| Total liabilities | ₩107.9B | ₩81.2B | ₩69.6B | ₩78.0B | ₩92.8B |
| Total equity | ₩86.5B | ₩105.8B | ₩104.1B | ₩106.4B | ₩72.7B |
| Paid-in capital | ₩85.0B | ₩117.0B | ₩120.5B | ₩125.3B | ₩125.3B |
| Debt/equity (source value) | 124.7% | 76.8% | 66.9% | 73.3% | 127.7% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2002-08-22
- Listed
- 05/11/18
- Employees
- 292
- Auditor
- 삼일회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1358110085019
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 비보존 제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.